Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIVEC for Intermediate-Risk NMIBC
2013-002628-18Phase 4Active
- Sponsor
- Combat Medical
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of mitomycin c in bladder cancer (2 arms), sponsored by Combat Medical. Primary endpoint: Disease-free survival at 24 months. Started Aug 2013; status: active.
02
Drugs
mitomycin c
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2013-002628-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002628-18.